Financial Performance - The company's revenue for Q3 2023 was ¥324,309,670.10, a decrease of 15.43% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥40,741,923.16, an increase of 5.02% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥38,415,738.94, up 7.55% from the previous year[5] - Total operating revenue for Q3 2023 was CNY 1,119,659,192.47, a decrease of 4.8% compared to CNY 1,175,028,595.83 in the same period last year[18] - Net profit for Q3 2023 was CNY 220,131,018.03, representing an increase of 16.2% compared to CNY 189,378,012.57 in Q3 2022[20] - The total comprehensive income for the third quarter was CNY 220,131,018.03, an increase from CNY 189,378,012.57 in the previous year, representing a growth of approximately 16.2%[21] Assets and Liabilities - Total assets at the end of Q3 2023 reached ¥3,123,660,776.60, reflecting a growth of 2.70% compared to the end of the previous year[5] - The company's total assets increased to CNY 3,123,660,776.60, up from CNY 3,041,677,568.76 at the end of the previous quarter[17] - Total liabilities decreased to CNY 369,138,465.83, down from CNY 417,934,051.11 in the previous quarter[17] - The company's non-current liabilities due within one year decreased by 35.81% to CNY 436,130.61, primarily due to a reduction in lease liabilities from its subsidiary Dongli Management[10] - Other current liabilities fell by 57.50% to CNY 2,414,317.39, mainly due to a decrease in advance sales payments and related VAT output tax[10] Cash Flow - Cash received from operating activities decreased by 53.02% to CNY 35,300,492.62, primarily due to the inclusion of subsidiary Jin Silin Pharmaceutical in the consolidated financial statements and a reduction in government subsidies[11] - The net cash flow from operating activities was CNY 195,942,182.47, down from CNY 247,371,958.46, indicating a decrease of about 20.7% year-over-year[24] - The total cash outflow from operating activities was CNY 910,016,803.08, down from CNY 963,245,791.67, a decrease of about 5.5%[24] - The cash inflow from financing activities was CNY 16,000,000.00, a decrease from CNY 69,800,000.00, reflecting a decline of about 77.0%[24] Earnings and Shareholder Information - The company's basic earnings per share for Q3 2023 was ¥0.0500, an increase of 5.04% year-on-year[5] - Basic and diluted earnings per share for the quarter were both CNY 0.2399, up from CNY 0.2074, marking an increase of approximately 15.1%[21] - The total number of ordinary shareholders at the end of the reporting period was 143,120, with the largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holding 34.39% of shares[12] Financial Position and Investments - The company reported a significant increase of 146.97% in trading financial assets, totaling ¥308,603,465.75 as of September 30, 2023[9] - The company experienced an 82.73% increase in notes receivable, amounting to ¥41,734,728.15[9] - Cash flow from investment activities saw a substantial decline of 69.26%, with cash recovered from investments dropping to CNY 155,900,000.00[10] - The net cash flow from investment activities was negative at CNY -198,053,599.96, a significant drop from CNY 15,542,442.47 in the prior year[24] Expenses and Income - Total operating costs decreased to CNY 864,866,529.85, down 8.3% from CNY 942,697,308.65 year-on-year[18] - Research and development expenses for Q3 2023 were CNY 44,544,568.46, a slight decrease from CNY 47,557,128.54 in Q3 2022[20] - Financial expenses decreased by 38.64% to CNY -19,539,774.32, attributed to increased interest income from deposits and reduced bank loan interest payments[10] - Other income dropped by 84.48% to CNY 2,386,702.42, mainly due to fewer government subsidies received compared to the previous year[10] - The company reported a financial income of CNY 18,416,709.43, an increase from CNY 11,324,426.38 in the same period last year[20] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20] Audit Status - The company has not undergone an audit for the third quarter report[25]

证券代码：002349 证券简称：精华制药 公告编号：2023-031 精华制药集团股份有限公司 关于召开2023年第二次临时股东大会通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 一、召开会议基本情况 1、股东大会届次：2023年第二次临时股东大会 2、股东大会的召集人：公司董事会 3、会议的合法合规性：公司第五届董事会第十七次会议审议通过了《关于 召开2023年第二次临时股东大会的议案》，决定召开公司2023年第二次临时股东 大会。本次股东大会的召开符合有关法律法规和公司章程的规定。 4、会议召开时间： 现场会议：2023年11月17日（星期五）下午14：30在江苏省南通市崇川区青 年中路198号国城生活广场办公楼A幢23层会议室召开。 网络投票时间：2023年11月17日。 通过深圳证券交易所交易系统进行网络投票的时间为2023年11月17日上午 9:15-9:25，9:30-11:30 和下午13:00～15:00；通过深圳证券交易所互联网投票 系统投票的时间为2023年11月17日上午9:15至下午15:00期间的任意时间。 ...

第一章 总则 第一条 为完善精华制药集团股份有限公司(以下称"公司"或"上市公司") 治理结构，规范公司运作，更好的维护公司整体利益，保障全体股东特别是中小 股东的合法权益不受损害，根据《中华人民共和国公司法》（以下称"《公司法》"）、 《中华人民共和国证券法》、《深圳证券交易所上市公司自律监管指引第 1 号-主 板上市公司规范运作》、《上市公司独立董事管理办法》以及公司章程（以下称"《章 程》"）的规定，特制订本独立董事工作制度（以下称"本制度"）。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的 上市公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可 能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 公司目前设独立董事三名。如果《章程》规定的董事会成员人数发 生变更，则公司董事会成员中应当有三分之一以上（包括三分之一）是独立董事， 且至少包括一名会计专业人士。 公司应当在董事会中设置审计委员会。审计委员会成员应当为不在上市公司 担任高级管理人员的董事，其中独立董事应当过半数，并由独立董事中会 ...

精华制药集团股份有限公司独立董事 因此，我们同意公司聘任天衡会计师事务所（特殊普通合伙）为公司2023 年度审计机构，并提交第五届董事会第十七次次会议审议。 二、公司独立董事的独立意见 公司拟续聘的财务报表审计机构天衡会计师事务所（特殊普通合伙）具备证 券业从业资格，曾先后为多家上市公司及拟上市公司提供审计服务，具备为上市 公司提供审计服务的经验和能力，能够满足公司财务审计工作的需要，独立对公 司财务状况进行审计。同时，天衡会计师事务所（特殊普通合伙）在公司近五年 度财务审计过程中，较好的完成了相关审计工作，续聘有利于保证公司审计业务 的连续性。 我们一致同意续聘天衡会计师事务所（特殊普通合伙）为公司2023年度审计 机构，并同意将该议案提交公司2023年第二次临时股东大会审议。 独立董事：王煦、冯巧根、马玲 关于第五届董事会第十七次会议相关议案的 独立意见 根据中国证监会《上市公司独立董事管理办法》、《深圳证券交易所上市公 司自律监管指引第1号—主板上市公司规范运作》及《公司独立董事工作制度》 等相关规定，作为精华制药集团股份有限公司（下称"公司"）独立董事，现就公 司第五届董事会第十七次会议相关议案发表如 ...

证券代码：002349 证券简称：精华制药 公告编号：2023-028 精华制药集团股份有限公司 第五届董事会第十七次次会议决议公告 表决结果：7票赞成；0票弃权；0票反对。 3、审议通过了《关于续聘会计师事务所的议案》。 《关于续聘会计师事务所的公告》详见《证券时报》、巨潮资讯网 (www.cninfo.com.cn)。该议案尚需提交股东大会审议。 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"、"本公司"、"精华制药"） 第五届董事会第十七次会议通知于2023年10月15日以传真、专人送达、邮件等形式 发出，会议于2023年10月26日（星期四）以通讯和现场相结合的方式在公司会议室 召开。公司部分监事、高级管理人员列席了会议，会议的召开符合《中华人民共和 国公司法》及《公司章程》的有关规定，会议的召集、召开合法有效。会议由董事 长尹红宇先生主持。 本次会议审议了以下议案： 1、审议通过了《2023年第三季度报告》。 《2023年第三季度报告》详见《证券时报》、巨潮资讯网(www.cninfo.com. ...

证券代码：002349 证券简称：精华制药 公告编号：2023-030 精华制药集团股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）于2023年10月26日召开第五 届董事会第十七次会议审议通过了《关于续聘会计师事务所的议案》，本次续聘会 计师事务所事项尚需提交股东大会审议，具体情况如下： 一、机构信息 天衡会计师事务所（特殊普通合伙）前身为始建于 1985 年的江苏会计师事务 所，1999 年脱钩改制，2013 年转制为特殊普通合伙会计师事务所。注册地址为江 苏省南京市建邺区江东中路 106 号 1907 室，经营范围为审查企业会计报表，出具 审计报告；验证企业资本，出具验资报告；办理企业合并、分立、清算事宜中的审 计业务，出具有关报告；基本建设年度财务决算审计；代理记账，会计咨询、税务 咨询、 管理咨询、会计培训。（依法须经审批的项目，经相关部门批准后方 可开 展经营活动） 2022 年末，天衡会计师事务所已提取职业风险基金 1,656.56 万元，购买的职 ...

证券代码：002349 证券简称：精华制药 公告编号：2023-029 精华制药集团股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记 载、误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）第五届监事会第十二次会议 通知于2023年10月15日以传真、专人送达、邮件等形式发出，会议于2023年10 月26日（星期四）以通讯和现场相结合的方式在公司会议室召开。会议应出席监 事3名，出席监事3名，会议的召开符合《中华人民共和国公司法》及《公司章程》 的有关规定，会议的召集、召开合法有效。会议由监事会主席薛红卫先生主持。 2023 年 10 月 30 日 本次会议审议通过了以下议案： 1、审议通过了《2023年第三季度报告》。 经过对公司2023年第三季度报告进行全面的审核后，监事会认为董事会编制 和审核公司2023年第三季度的程序符合法律、行政法规和中国证监会的相关规定， 报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 表决结果：3票赞成；0票弃权；0票反对。 特此公告。 ...

证券代码：002349 证券简称：精华制药 公告编号：2023-027 精华制药集团股份有限公司 关于公司股东减持股份完成的公告 股东南通综艺投资有限公司、江苏综艺控股集团有限公司、昝圣达先生保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 精华制药集团股份有限公司（以下简称"公司"或"本公司"）于2023年3月18 日披露了《关于持股5%以上股东减持股份计划的预披露公告》，具体内容详见 《证券时报》、巨潮资讯网(www.cninfo.com.cn)。公司股东南通综艺投资有限公 司（以下简称"综艺投资"）、昝圣达先生拟自2023年4月11日起的6个月内通过 证券交易所集中竞价交易方式减持公司股份不超过16,283,618股（不超过公司总 股份的2%），且任意连续90日内减持股份的总数不超过公司总股本的1%。 近日，公司收到综艺投资、江苏综艺控股集团有限公司（以下简称"综艺控 股"）、昝圣达先生减持计划完成的告知，其减持计划已完成。本次减持计划完 成情况具体内容如下： 一、已披露的减持计划主要内容 本次减持前， ...

证券代码：002349 证券简称：精华制药 | --- | --- | --- | |----------------|---------------|-------------| | 投资者关系活动 | √特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | | | | | □新闻发布会 | □路演活动 | □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 西部证券 丁健行 时间 15：00-16：00 地点 线上 上市公司接待人 董事会秘书 王剑锋 员姓名 证券事务代表 樊屹秋 主要介绍公司半年度报告业绩情况，以及公司主要产品。 投资者关系活动 主要内容介绍 附件清单（如有） 无 日期 2023 年 8 月 28 日 精华制药集团股份有限公司投资者关系活动记录表 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥795,349,522.37, representing a 0.48% increase compared to ¥791,546,445.79 in the same period last year[24]. - The net profit attributable to shareholders increased by 18.85% to ¥154,607,331.58 from ¥130,082,099.19 year-on-year[24]. - The net profit after deducting non-recurring gains and losses rose by 24.86% to ¥150,284,938.85 compared to ¥120,363,373.59 in the previous year[24]. - The basic earnings per share increased by 18.84% to ¥0.1899 from ¥0.1598 in the same period last year[24]. - The total assets at the end of the reporting period were ¥3,071,370,283.37, a 0.98% increase from ¥3,041,677,568.76 at the end of the previous year[24]. - The net assets attributable to shareholders increased by 3.78% to ¥2,491,664,487.10 from ¥2,400,966,083.66 at the end of the previous year[24]. - The net cash flow from operating activities decreased by 30.02% to ¥99,763,312.02 from ¥142,554,001.49 in the same period last year[24]. - The weighted average return on equity increased to 6.24% from 5.65% year-on-year[24]. - The company achieved consolidated sales revenue of CNY 795.35 million, a year-on-year increase of 0.48%[43]. - The net profit attributable to the parent company was CNY 155 million, representing a year-on-year growth of 18.85%[43]. - Operating cash flow net amount was CNY 99.76 million, a decrease of 30.02% compared to the previous year[49]. - Research and development investment decreased by 14.96% to CNY 28.78 million[49]. - Sales expenses increased by 3.89% to CNY 107.72 million, while management expenses decreased by 22.10% to CNY 52.83 million[49]. - The company reported a total revenue of 4,322,392.73, with a significant portion attributed to non-operating income[29]. Product and Market Development - The main business activities include the R&D, production, and sales of traditional Chinese medicine, chemical raw materials, and biopharmaceuticals[32]. - Key products include Wang's Baorichuan Pill, which is used for various digestive and respiratory issues, and has been recognized in multiple medical guidelines[36][38]. - The company has a unique product advantage with proprietary formulas for its key products, including Wang's Baorichuan Pill and Jide Sheng Snake Medicine Tablet, which are classified as state secrets[36][37]. - The company emphasizes a vertically integrated business model, enhancing growth through internal management and expanding its presence across the pharmaceutical supply chain[39]. - The company is actively involved in the development of new products and technologies to enhance its market position[39]. - The company is actively promoting the "going out" strategy for traditional Chinese medicine, with successful registration in Macau[43]. - The company has obtained European COS certification for five products, and several products have passed FDA on-site audits[41]. - The company completed the registration of a new product, Huberzong, in 19 European countries, with nearly 6 tons of commercial orders obtained[44]. - The company has established a 30,000-acre organic Chinese medicinal herb planting base in Gansu Province, contributing to local employment by hiring 71 people and purchasing local medicinal materials worth 25.9844 million yuan[123]. - The company has conducted three training sessions for over 150 participants on organic planting techniques for traditional Chinese medicinal herbs, enhancing local farmers' income and preventing poverty recurrence[123]. - The company is committed to investing in local organic medicinal herb cultivation and processing, aligning with local government rural revitalization efforts[123]. Environmental and Safety Compliance - The company adheres to strict environmental standards for emissions and waste management across its subsidiaries[80]. - The company has obtained the latest pollutant discharge permit, valid until March 12, 2028[84]. - The company’s wastewater and air emissions have passed self-inspection, with solid waste and noise approved by the local environmental protection bureau[85]. - The company’s first phase project completed environmental protection acceptance in April 2022, and the discharge permit was obtained in February 2022[87]. - The company’s wastewater discharge concentration for COD is 233.574 mg/l, below the standard limit of 500 mg/l[88]. - The company has established wastewater treatment facilities with automatic monitoring equipment to ensure compliance with discharge standards[92]. - The company has implemented various pollution discharge standards, including those for volatile organic compounds and wastewater[83]. - The company has a comprehensive waste management strategy, including the treatment of solid waste and sludge through authorized channels[94]. - The company has a dedicated safety and environmental management department to oversee compliance with safety and environmental regulations[104]. - The company conducts regular monitoring of wastewater and air emissions, including online monitoring every two hours for wastewater[105]. - The company has conducted emergency drills to enhance employees' capabilities in handling environmental incidents[104]. - The company’s environmental emergency response plan was reviewed and approved in July 2022[103]. Shareholder and Financial Management - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[5]. - The company has distributed a total cash dividend of 147 million yuan from 2021 to 2023, emphasizing its commitment to shareholder returns[118]. - The company has not reported any non-compliance issues or financial irregularities during the reporting period[126][127][128]. - The company reported a significant increase in sales to related parties, with actual sales amounting to CNY 97,500 (approximately USD 14,000) during the reporting period[134]. - The company has a total of CNY 29.9 million (approximately USD 4.2 million) in entrusted financial management products, all of which are bank financial products with no overdue amounts[147]. - The total number of ordinary shareholders at the end of the reporting period is 142,450[156]. - The largest shareholder, Nantong Industrial Holding Group, holds 34.39% of the shares, totaling 279,994,660 shares[156]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[160]. Future Outlook and Strategic Initiatives - The company plans to expand its market presence by entering three new regions by the end of 2024[194]. - A new product line is expected to launch in Q4 2023, which is anticipated to contribute an additional 300 million yuan in revenue[194]. - The company is exploring potential acquisitions to enhance its product portfolio and market share[194]. - The company has set a performance guidance of 2.2 billion yuan in revenue for the next half of the year, indicating a growth target of 15%[193]. - The company has initiated a strategic partnership with a leading biotech firm to enhance its product pipeline and accelerate development timelines[197]. - The company aims to improve shareholder value through effective capital management strategies[200].